2024 annual financial data
BridgeBio Oncology Therapeutics 2024 Operating cash flow margin
Direct answer
Operating cash flow margin was Not calculable.
Operating income was -80,863,000 USD and net income was -74,275,000 USD.
Operating cash flow was -763,820 USD.
Get free BridgeBio Oncology Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -80,863,000 USD
- Net income
- -74,275,000 USD
- Operating cash flow
- -763,820 USD